Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells

For the first time, the results of an immunohistochemical study of CD146 in MM and reactive mesothelial cells

Hiroshi Minato


Scholarcy highlights

  • List biomarkers used for the differential diagnosis between malignant mesothelioma and reactive mesothelial cells
  • In this study, we conducted a comparative immunohistochemical analysis of MM and RMC cases using antibodies targeting IMP3, glucose transporter 1, CD146, epithelial membrane antigen, and desmin to determine which of these antibodies would provide the best combination for distinguishing between MM and RMCs
  • All materials from RMC cases were benign lung tissues surgically removed from patients with pneumothorax who did not have any tumor tissues
  • We used the Receiver operating characteristic curves for IMP3, GLUT1, EMA, CD146, and desmin to assess the ability of each marker to distinguish between MM and RMC ❚Figure 3❚
  • Shi et al reported that of the MM cases, 82% showed IMP3 expression in more than 50% of malignant cells, 6% showed IMP3 expression in 25% to 50% of malignant cells, and 12% showed IMP3 expression in 5% to 25% of malignant cells
  • Considering the optimal cutoff points on the ROC curve, if the cutoff points were set at 30% for IMP3 and 10% for GLUT1, the sensitivity and specificity between MM and RMC would be 100% and 95%, respectively, when using the combination of only these two markers
  • This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module

Need more features? Save interactive summary cards to your Scholarcy Library.